Licensing agreement for ESETEC-based production of antibody fragment PB2452Licensing Agreement • June 14th, 2024
Contract Type FiledJune 14th, 2024PhaseBio obtains the right to use both WACKER’s ESETEC-based production strain and WACKER’s ESETEC technology to manufacture and commercialize the antibody fragment.